Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Parkinson's muscle supplement study pulled before it began

NCT ID NCT06604065

Disease control Sponsor: University of Arkansas Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to see if a special nutritional supplement (AMS2434) could help people with Parkinson's disease build stronger muscles and improve brain function. It was designed for adults aged 55 and older with mild to moderate Parkinson's. However, the study was withdrawn before any participants were enrolled, so no results are available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Started

Mar 2026

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 55 years or older * Clinical diagnosis of idiopathic Parkinson Disease * Hoehn and Yahr stage 2-3 * Stable medication regimen with L-DOPA/carbidopa for at least 4 weeks prior to study entry Exclusion Criteria: * Findings suggestive of atypical or secondary Parkinsonism, including cerebellar sign * Use of anticoagulation drugs (including aspirin and Plavix) within one week of the protocol * Allergy to lidocaine * Supranuclear gaze palsy, apraxia, prominent autonomic failure, or other cortical signs * Multiple strokes with stepwise progression of symptoms * Neuroleptic treatment at time of study entry or time of onset of Parkinsonism * Inability to walk without a cane or walker * Deep brain stimulation * Montreal Cognitive Assessment (MoCA) score \<18 * Use of investigational drugs * Early Alzheimer's disease * Frontotemporal dementia of dementia with Lewy bodies * Major depression treated with SSRIs * Individuals with auditory or visual hallucinations * Individuals taking drugs that cause Parkinsonism like symptoms such as antipsychotics, anti-emetics, prokinectic and anti-seizure medications

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease

More trials for these conditions

Other studies related to the condition(s) this trial covers.